Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05814627 · ClinicalTrials.gov registry record · Phase 3
Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
A Phase 3 study of Rheumatoid Arthritis, sponsored by AbbVie.
- Active
- Registry status
- Phase 3
- Development phase
- 487
- Enrollment target
- 20
- Study locations
NCT05814627 is a Phase 3 study of Rheumatoid Arthritis that is active but no longer recruiting, run by AbbVie. The registered enrollment target is 487 participants, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT05814627, a Phase 3 study of Rheumatoid Arthritis, is active but no longer recruiting, sponsored by AbbVie.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 487 participants
- Enrollment target
- 20
- Study locations
Study Summary
Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-inhibitor who are on a stable dose of methotrexate (MTX). Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for the treatment of RA. This study is double-blinded means that neither the participants nor the study doctors will know who will be given upadacitinib and who will be given adalimumab. Study doctors put the participants in 1 of the 2 groups, called treatment arms randomly, to receive either upadacitinib or adalimumab. There is 1 in 2 chance that participants will receive adalimumab. Each group consists of 2 periods. Approximately 480 participants diagnosed with RA will be enrolled in approximately 250 sites across the world. Participants will receive the oral upadacitinib once daily and matching adalimumab placebo every other week, or the subcutaneous adalimumab every other week and matching upadacitinib placebo once daily during Period 1. Eligible participants will continue to receive same study treatment in Period 2 as assigned in Period 1 and will be followed for 30 days and 70 days. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, checking for side effects and completing questionnaires.
Conditions Studied
Interventions
- DRUG Adalimumab
- DRUG Upadacitinib
- DRUG Upadacitinib Matching Placebo
- DRUG Adalimumab Matching Placebo
Study Locations (20)
California
- Providence - St. Jude Medical Center /ID# 252690 - Fullerton
- Newport Huntington Medical Group /ID# 252687 - Huntington Beach
- Purushotham & Akther Kotha MD, Inc /ID# 252704 - La Mesa
- Valerius Medical Group & Research Center of Greater Long Beach, Inc /ID# 252692 - Los Alamitos
- Rheumatology Center of San Diego /ID# 255038 - San Diego
- Millennium Clinical Trials /ID# 252689 - Thousand Oaks
- The Lundquist Institute at Harbor-UCLA Medical Center /ID# 252691 - Torrance
- Comprehensive Rheumatology Center /ID# 252688 - Woodland Hills
Arizona
- AZ Arthritis and Rheumotology Research, PLLC - Flagstaff /ID# 253431 - Flagstaff
- Arizona Arthritis and Rheumatology Research - Glendale Office /ID# 255018 - Glendale
- Sun Valley Arthritis Center Ltd. /ID# 254654 - Peoria
- Arizona Arthritis & Rheumatology Associates - East Bell Road /ID# 253432 - Phoenix
- Arizona Arthritis & Rheumatology Associates - East Bell Road /ID# 255021 - Phoenix
- Arizona Arthritis & Rheumatology Associates - Tucson /ID# 255017 - Tucson
Colorado
- University of Colorado Hospital /ID# 254617 - Aurora
- Denver Arthritis Clinic /ID# 254058 - Denver
- Tekton Research - Fort Collins - East Harmony Road /ID# 255036 - Fort Collins
Florida
- Arthritis and Rheumatic Disease Specialties /ID# 260583 - Aventura
- Rheumatology Associates of South Florida (RASF) - Clinical Research /ID# 253733 - Boca Raton
Arkansas
- Arthritis and Rheumatism Associates /ID# 254013 - Jonesboro
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 487 participants |
| Start Date | 2023-06-15 |
| Est. Completion | 2026-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05814627
The ClinicalTrials.gov registry entry for NCT05814627 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 487 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,688-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (90% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 4 interventions - of which Adalimumab is the first listed.
NCT05814627 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Arizona, Colorado.
Frequently Asked Questions
What is clinical trial NCT05814627 about?
NCT05814627 is a clinical study titled "Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis". Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how safe and effective upadacitinib is in treating RA when compared to adalimumab in adult participants with inadequate response or intolerance to one TNF-...
What is the current status of trial NCT05814627?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 487 participants. The study started on 2023-06-15. Estimated completion is 2026-07.
What conditions does trial NCT05814627 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis.
What interventions are being tested in trial NCT05814627?
The interventions under investigation include: Adalimumab (DRUG), Upadacitinib (DRUG), Upadacitinib Matching Placebo (DRUG), Adalimumab Matching Placebo (DRUG).
Who is sponsoring clinical trial NCT05814627?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05814627 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
RECRUITING · Phase 3
-
Ra-pro Pragmatic Trial
RECRUITING · Phase 3
-
Vagus Nerve Stimulation for Moderate to Severe Rheumatoid Arthritis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
ACTIVE NOT RECRUITING · Phase 3
-
A Study in Participants With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.